Search

Actinomycetes isolated from Iran soil habitats were tested for the capacity to produce compounds which can protect neurons from cell death generated by oxidative stress in NT2 neurons. Confirmation of our initial hit was accomplished via the determination of amyloid β level using the enzyme-linked immunosorbent assay test. The most interesting amyloid β formation inhibitor discovered in our study was a secondary metabolite which was produced by strain HM45. This bioactive strain was identified as a strain of Streptomyces antibioticus DSM 40234 using polyphasic approach. The strain HM45 was deposited in Deutsche Sammlung von Mikroorganismen und Zellkulturen as S. antibioticus DSM 41955 and University of Tehran Microorganisms Sollection as S. antibioticus UTMC 00105. This work is the first report on efficiency of an actinomycete metabolite in prohibition of neurons death caused by amyloid β formation. [ABSTRACT FROM AUTHOR]

Abstract: Alzheimer''s disease (AD) a progressive neurodegenerative disorder of later life, is characterized by brain deposition of amyloid β-protein (Aβ) plaques, accumulation of intracellular neurofibrillatory tangles, synaptic loss and neuronal cell death. There is significant evidence that oxidative stress is a critical event in the pathogenesis of AD. In the present study Aβ formation was induced in NT2N neurons, one of the most appropriate cell line models in AD. Our results indicate that oxidative stress resulting from the treatment of H2O2/FeSO4 and/or 4-hydroxy-2-noenal (HNE) can be inhibited in the presence of tBHQ, a known inducer of nuclear factor-erythroid 2 related factor 2 (Nrf2) in NT2N neurons and can therefore be used to elucidate the relationship between oxidative stress, Aβ formation and Nrf2. The role of Nrf2 was confirmed using retinoic acid as an inhibitor of Nrf2. It provides the first documentation that tBHQ not only protects the neurons against cell death but also decreases amyloid β formation. Moreover, the results indicate that oxidative stress fosters Aβ formation in NT2N neurons, creating a vicious neurodegenerative loop. [Copyright &y& Elsevier]

Highlights • i.p. administration of CEPO-Fc prevents Aβ 25–35 -induced spatial learning and memory impairment. • Aβ 25–35 -mediated memory loss is associated with MAPKs (P38, ERK, JNK) hyperactivity and MMP-2 overexpression in hippocampus. • Memory deterioration induced by Aβ 25–35 is related to disruption in Akt/GSK-3β signaling. • i.p. CEPO-Fc treatment reverses the effect of Aβ 25–35 on hippocampal P38, ERK, Akt/GSK-3β and MMP-2. Abstract Alzheimer’s disease (AD) is a debilitating neurodegenerative disease, characterized by extracellular deposition of senile plaques, mostly amyloid β-protein (Aβ) and neuronal loss. The neuroprotective effects of erythropoietin (EPO) have been reported in some models of neurodegenerative disease, but because of its hematopoietic side effects, its derivatives lacking hematopoietic bioactivity is recommended. In this study, the neuroprotective effects of carbamylated erythropoietin-Fc (CEPO-Fc) against beta amyloid-induced memory deficit were evaluated. Adult male Wistar rats weighing 250–300 g were bilaterally cannulated into CA1. Aβ 25–35 was administered intrahippocampally for 4 consecutive days (5 μg/2.5 μL/each side/day). CEPO-Fc (500 or 5000 IU) was injected intraperitoneally during days 4–9. Learning and memory performance of rats was assessed on days 10–13 using Morris Water Maze, then hippocampi were isolated and the amount of activated forms of hippocampal MAPKs’ subfamily, Akt/GSK-3β and MMP-2 were analyzed using Western blot. From the behavioral results, it was revealed that CEPO-Fc treatment in both 500 and 5000 IU significantly reversed Aβ-induced learning and memory deterioration. From the molecular analysis, an increment of MAPKs and MMP-2 activity and an imbalance in Akt/GSK-3β signaling after Aβ 25–35 administration was observed. CEPO-Fc treatment prevented the elevation of hippocampal of P38, ERK, MMP-2 activity and also Akt/GSK-3β signaling impairment induced by Aβ 25–35 but it had no effect on JNK. It seems that CEPO-Fc prevents Aβ-induced learning and memory deterioration, and also modulates hippocampal MAPKs, Akt/GSK-3β and MMP-2 activity. This study suggests that CEPO-Fc can be considered as a potential therapeutic strategy for memory deficits like AD. [ABSTRACT FROM AUTHOR]

Alzheimer disease (AD) is a progressive neurodegenerative disease characterized by extracellular deposits of beta amyloid (Aβ) and neuronal loss particularly in the hippocampus. Accumulating evidences have implied that insulin signaling impairment plays a key role in the pathology of AD; as much as it is considered as type 3 Diabetes. MAPKs are a group of signaling molecules which are involved in pathobiology of AD. Therefore this study was designed to investigate if intrahippocampal insulin hinders Aβ-related memory deterioration, hippocampal apoptosis and MAPKs signaling alteration induced by Aβ. Adult male Sprague-Dawely rats weighing 250-300 g were used in this study. The canules were implanted bilaterally into CA1 region. Aβ25-35 was administered during first 4 days after surgery (5 μg/2.5 μL/daily). Insulin treatment (0.5 or 6 mU) was done during days 4-9. The animal's learning and memory capability was assessed on days 10-13 using Morris water maze. After finishing of behavioral studies the hippocampi was isolated and the amount of hippocampal cleaved caspase 3 (the landmark of apoptosis) and the phosphorylated (activated) forms of P38, JNK and ERK was analyzed by western blot. The results showed that insulin in 6 but not 0.5 mU reversed the memory loss induced by Aβ25-35. Western blot analysis revealed that Aβ25-35 induced elevation of caspase-3 and all 3 MAPks subfamily activity, while insulin in 6 mu restored ERK and P38 activation but has no effect on JNK. This study disclosed that intrahippocampal insulin treatment averts not only Aβ-induced memory deterioration but also hippocampal caspase-3, ERK and P38 activation. [ABSTRACT FROM AUTHOR]

Alzheimer disease (AD) is characterized by accumulation of beta amyloid (Aβ) and neuronal loss, particularly in the hippocampus. Direct central administration of this peptide was suggested as a route to create an animal model of AD. Although there are some studies indicating that a single dose of Aβ induces AD-like learning and memory impairment, this model is not usually reproducible especially in rat. Then one of the aims of this study was to explore a more reliable method to trigger AD-like behavioral impairments in rat through a series of pilot studies. In other step, according to some controversies about roles of MAPKs (P38, JNK and ERK) in AD, these kinases were assayed in beta amyloid-treated rats with or without memory impairment. A series of pilot studies was done to assess if a single Aβ injection (5, 10, 15µg/each side) induces reproducible memory impairment. Because of the failure of that set of studies, another set of experiment with repeated Aβ administration during four days was carried out. The results showed that in contrast to single treatment of beta amyloid, its repeated administration (5µg/2.5µl each side/day) during 4 days led to memory deterioration. Hippocampal western blot analysis revealed that behavioral impairment is in parallel with greater apoptosis and MAPKs activation. This study introduces a new method for inducing AD models by repeated intra-CA1 injection of Aβ25–35. Additionally it elucidates how caspase-3 and MAPKs activity differ between beta amyloid-treated rats with or without learning and memory impairment. [ABSTRACT FROM AUTHOR]

Abstract: Increased oxidative stress is a widely accepted factor in the development and progression of Alzheimer’s disease. Here we introduced alginate – an antioxidant oligosaccharide – as a protective agent on NT2 neural cell line against H2O2/FeSO4-induced cell death. Our results demonstrate that alginate not only protects the neurons against cell death, as measured by MTT test and caspase-3 activity determination, but also decreases amyloid β formation. In the present study we could induce Aβ formation through oxidative stress in NT2 neurons, one of the most appropriate cell line models in Alzheimer’s disease and provided the first documentation that alginate can be neuroprotective by suppressing Aβ formation. We further showed that alginate exerts its protective effect by up regulation of HO-1, γ-GCS, Hsp-70, Nrf2 and inhibiting caspase-3 and NF-κB. This study raises the possibility of developing alginate as a potential neuroprotective agent. [Copyright &y& Elsevier]

Intracerebroventricular (icv) administration of streptozotocin (STZ) has been used as a metabolic model of sporadic Alzheimer's disease (AD). Erythropoietin (EPO) possesses neuroprotective and memory-improving effects, which might be advantageous in treating different characteristics of AD. Nevertheless, the hematopoietic effect of EPO has hindered its application as a neuroprotective agent. Previous studies have shown that a new Epo derivative called carbamylated Erythropoietin-Fc (CEPO-Fc), yield noticeable neuroprotective effects without affecting hematopoiesis. In this study, the neuroprotective effects of CEPO-Fc on icv-STZ induced memory impairment and hippocampal apoptosis were examined. Adult male Wistar rats weighing 250−300 g were used. STZ was administered on days 1 and 3 (3 mg/kg in divided doses/icv), and CEPO-Fc was administered at the dose of 5000 IU/ip/daily during days 4–14. The animals were trained in Morris water maze during days 15–17, and the memory retention test was performed on the 18th day. Following behavioral studies, the animals were sacrificed and their hippocampi isolated to determine the amounts of cleaved caspase-3 (the landmark of apoptosis). The results showed that CEPO-Fc treatment at the dose of 5000 IU/kg/ip was able to prevent the learning and memory deficit induced by icv-STZ. Western blot analysis revealed that STZ prompted the cleavage of caspase-3 in the hippocampus while pretreatment with CEPO-Fc significantly reduced the cleavage of this protein. Collectively, our findings suggest that CEPO-Fc could restore STZ-induced learning and memory impairment as well as apoptosis in the hippocampal region in a rat model of sporadic AD induced by icv-STZ. [ABSTRACT FROM AUTHOR]